In their report BRFS was 81% at 2 years and 71% at 5 years follow-up, with a longer BRFS in patients with a higher PSA decrease after treatment; in addition, a very low urinary incontinence rate was observed with only 2.7% of major adverse events. This evidence concerns the gene KLK3 and Urinary incontinence.